Integrative medicine research · 2026
Comparative effectiveness of Chinese herbal medicine versus liraglutide for weight loss in adults with obesity: A 12-month real-world target trial emulation study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liao Yu-Ning, Yang Tsung-Hsien, Lu Yi-Chin, Tseng Liang-Wei, Yang Ching-Wei, Huang Yu-Tung, Chen Hsing-Yu
Аннотация
BACKGROUND: Chinese herbal medicine (CHM) is commonly used for weight control in Taiwan. This study aimed to compare the effectiveness and mechanisms of a fixed combination of CHM with liraglutide using a target trial emulation real-world study.
METHODS: From January 1, 2013, to December 31, 2018, subjects from the multi-institutional Chang Gung Research Database (CGRD) with a BMI ≥ 25 kg/m² received a fixed combination of Ma-Xing-Gan-Shi-Tang and Coptis chinensis Franch, namely Ma-Xing-Gan-Shi-Tang and Coptis chinensis Franch LOwering Weight formula (MCLOW), were compared with those using liraglutide for weight control for a 12-month follow-up course with overlap weighting for baseline inequality.
RESULTS: Among 376 subjects, 135 (35.9%) used MCLOW, who lost more weight from baseline (-6.07 [95% CI:6.90 to -5.24] vs. -1.66 [95% CI:2.22 to -1.1] kg; p-value < 0.001), and had a higher proportion achieved weight reductions of ≥ 5% and ≥ 10% (68.15% vs. 23.65%, p < 0.001 and 32.59% vs. 7.05%, p-value < 0.001, respectively). The results were consistent with overlap and inverse probability of treatment weighting models. By using network pharmacology, use of MCLOW was associated with lipid metabolism and immune-related pathways, while liraglutide was linked to insulin-secretion pathways.
CONCLUSION: The CHM formula MCLOW appears to have promising effects on weight loss, with mechanisms differing from but complementary to those of Western medicines.
METHODS: From January 1, 2013, to December 31, 2018, subjects from the multi-institutional Chang Gung Research Database (CGRD) with a BMI ≥ 25 kg/m² received a fixed combination of Ma-Xing-Gan-Shi-Tang and Coptis chinensis Franch, namely Ma-Xing-Gan-Shi-Tang and Coptis chinensis Franch LOwering Weight formula (MCLOW), were compared with those using liraglutide for weight control for a 12-month follow-up course with overlap weighting for baseline inequality.
RESULTS: Among 376 subjects, 135 (35.9%) used MCLOW, who lost more weight from baseline (-6.07 [95% CI:6.90 to -5.24] vs. -1.66 [95% CI:2.22 to -1.1] kg; p-value < 0.001), and had a higher proportion achieved weight reductions of ≥ 5% and ≥ 10% (68.15% vs. 23.65%, p < 0.001 and 32.59% vs. 7.05%, p-value < 0.001, respectively). The results were consistent with overlap and inverse probability of treatment weighting models. By using network pharmacology, use of MCLOW was associated with lipid metabolism and immune-related pathways, while liraglutide was linked to insulin-secretion pathways.
CONCLUSION: The CHM formula MCLOW appears to have promising effects on weight loss, with mechanisms differing from but complementary to those of Western medicines.